PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsBlood test for eight common cancers offers promise

BioNews

Blood test for eight common cancers offers promise

Published 23 January 2018 posted in News and appears in BioNews 934

Author

Dr Loredana Guglielmi

PET BioNews

Scientists have developed a single blood test to detect eight common cancer types and their location of origin within the body...

Scientists have developed a single blood test to detect eight common cancer types and their location of origin within the body.

CancerSEEK is a non-invasive screening test or liquid biopsy aimed at tracking tumour formation and progression from fragments of tumour DNA in the bloodstream. Unlike previous liquid biopsy tests which tend to assess only the presence of circulating tumour DNA (ctDNA), CancerSEEK simultaneously detects cancerous proteins. By using a combination of eight aberrant proteins and 16 ctDNA mutations, the new test is able to identify ovarian, liver, stomach, pancreatic, esophageal, colorectal, lung and breast cancers, which account for 60 percent of the estimated cancer deaths in the US.

'The use of a combination of selected biomarkers for early detection has the potential to change the way we screen for cancer, and it is based on the same rationale for using combinations of drugs to treat cancers,' said Dr Nickolas Papadopoulos, at Johns Hopkins University School of Medicine in Baltimore, Maryland, who led the study. The research was published in Science.

The test was given to around 1000 patients with non-metastatic cancers. CancerSEEK correctly diagnosed 70 percent of the cases and successfully excluded false positive results with a specificity above 99 percent. However, the performance of the test varied significantly with the type of tumour: it detected 98 percent of ovarian cancers, but only 33 percent of breast cancers. In addition, the test outcomes substantially improved when more advanced cancerous lesions - stage III diseases, were examined.

'This paper is provocative,' Professor Alberto Bardelli, at the Candiolo Cancer Institute in Turin, Italy told Nature News. 'It points to the fact that we should stop looking at a little part of the picture. Instead, we need to see all of the sources of information in the blood.'

CancerSEEK could be potentially administered by primary care providers at the time of other routine blood work, and the researchers estimate that the cost of the test could be less than US$500, comparable with a colonoscopy.

Experts noted some drawbacks of the study. 'This looks promising but with several caveats and a significant amount of further research is needed before we can even contemplate how this might play out in screening settings,' said Dr Mangesh Thorat, deputy director of the Barts Clinical Trials Unit, Queen Mary University of London. 'This is only a case-control study, and therefore needs further evaluation in large cohorts more representative of general population where such screening might be introduced.'

Researchers led by Dr Papadopoulos have begun to address those concerns and have started a new study that will test CancerSEEK in at least 10,000 healthy individuals.

Related Articles

PET BioNews
News
23 August 2019 • 1 minute read

Blood test detects ovarian cancer two years earlier

by Emma Laycock

Scientists have developed a blood test that may be able to detect ovarian cancer up to two years earlier than other methods...

PET BioNews
News
2 August 2019 • 2 minutes read

Liquid biopsy could detect breast cancer recurrence earlier than scan

by Dr Molly Godfrey

A newly developed blood test can spot breast cancer relapses almost a year before they are clinically detectable...

PET BioNews
News
21 June 2019 • 2 minutes read

New blood test could help diagnose ovarian cancer

by Emma Laycock

Scientists have discovered a set of biomarkers in the blood that could indicate ovarian cancer, which could be used to help diagnose the disease...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
1 June 2018 • 2 minutes read

Liquid biopsy test offers hope for ten cancers

by Shaoni Bhattacharya

A new blood test which can detect ten cancers at an early stage is offering hope as a way to screen for multiple cancers...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
26 February 2018 • 2 minutes read

Fathers may pass ovarian cancer risk to daughters

by Dr Rosie Morley

Scientists have identified a new gene for ovarian cancer risk that may be passed down from fathers to their daughters...

PET BioNews
News
31 August 2017 • 2 minutes read

Liquid biopsy may help target prostate cancer treatment

by Charlotte Spicer

A new three-in-one blood test could progress personalised treatment for patients with prostate cancer...

PET BioNews
News
24 August 2017 • 2 minutes read

Liquid DNA biopsies could be used for cancer screening

by Dr Loredana Guglielmi

US researchers have developed a new blood test to detect cancer-related DNA alterations before patients experience symptoms...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 May 2017 • 2 minutes read

Blood test could detect and locate cancer at early stage

by Dr Loredana Guglielmi

Researchers have developed a new blood test that can not only detect cancer at an early stage, but can also indicate where the tumour is located in the body...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 May 2017 • 2 minutes read

DNA tests spot returning lung cancer a year before scans

by Dr Loredana Guglielmi

Blood tests for tumour DNA could predict relapse of the most common type of lung cancer up to one year before clinical signs show up on patient's scans...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 November 2015 • 1 minute read

Liquid biopsy could track cancer progress in real time

by Ayala Ochert

Scientists say it may be possible to track the progress of cancer — and cancer treatment — in real time from fragments of tumour DNA that are shed into the bloodstream...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Friends share closer genetics than strangers

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

27 June 2022 • 2 minutes read

UK report reveals public attitudes to fertility, genomics and embryo research

27 June 2022 • 2 minutes read

Shortage of sperm donors despite men willing to donate

27 June 2022 • 2 minutes read

North East London CCG proposes offering three funded IVF cycles

27 June 2022 • 2 minutes read

Fibrosis drugs reverse ovarian ageing in mice

27 June 2022 • 2 minutes read

Gene implicated in motor neurone diseases discovered

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856